Variable name | Catastrophising | Coping | ||||
---|---|---|---|---|---|---|
p Value (UVA) | Correlation coefficient | p Value (MVA) | p Value (UVA) | Correlation coefficient | p Value (MVA) | |
SF-12 PCS | <0.001 | −0.250** | NS | |||
SF-12 MCS | <0.001 | −0.443** | <0.001 | 0.001 | 0.171** | NS |
SLAQ score | <0.001 | 0.475* | 0.042 | NS | NS | |
VFS score | <0.001 | 0.367* | NS | |||
SLICC/ACR DI | <0.001 | 0.192* | NS | |||
Number of concomitant diseases | <0.001 | 0.202* | NS | |||
Number of lupus-specific drugs | <0.001 | 0.204* | 0.004 | NS | NS | |
Inability to work | 0.001 | 0.213* | NS | |||
Degree of disability (%) | 0.003 | 0.169** | NS | |||
Pain in the last 7 days | <0.001 | 0.420* | 0.034 | NS | NS | |
Impairment in the last 7 days | <0.001 | 0.388* | NS | |||
Disease flares during last 3 months | <0.001 | 0.280* | NS | |||
Social participation | NSX | NS | 0.001X | 0.006 |
Data are p values and correlation coefficients. Correlations were carried out by Spearman's (*) and Pearson's (**) correlations. The p values for catastrophising and coping in the UVA were derived from Spearman's and Pearson's correlation or from the Mann–Whitney U test (x). The p values for catastrophising and coping in the MVA were derived from ANOVA (analysis of variance). Only complete cases (n=323) were included in the MVA.
SF-12 MCS, SF-12 Mental Component Summary; SF-12 PCS, SF-12 Physical Component Summary; SLAQ, Systemic Lupus Activity Questionnaire; SLICC/ACR DI, Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index; VFS, Vanderbilt Fatigue Score.